FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 63 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Dostarlimab February 26, 2021 Invasive Lobular Carcinoma Is Invisible On Mammograms, Isn’t A Lump April 4, 2019 Groundbreaking Trial Results Expand Treatment Options for Some People with Bladder... November 30, 2023 EMA Recommends Granting a Marketing Authorisation for Nivolumab / Relatlimab August 11, 2022 Load more HOT NEWS Mother and Daughter Graduate Nursing Masters Programs Together After Breast Cancer... Re-Thinking Community The Doctor Will See You Now…On the Screen 2-Year-Old Cancer Survivor With Down Syndrome Hears For First Time: ‘Her...
